[Does molecular targeted therapy change the treatment for lung cancer?].
Nakanishi
Yoichi
Y
Department of Clinical Medicine, Internal Medicine, Division of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002453:Cell Cycle; D000077156:Gefitinib; D018773:Genes, erbB-1 / Q000235:genetics; D015316:Genetic Therapy; D008175:Lung Neoplasms / Q000628:therapy*; D009389:Neovascularization, Pathologic; D011799:Quinazolines / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000235:genetics; D014614:Vaccines, Synthetic
D000970:Antineoplastic Agents; D011799:Quinazolines; D016159:Tumor Suppressor Protein p53; D014614:Vaccines, Synthetic; D040262:Receptors, Vascular Endothelial Growth Factor; D000077156:Gefitinib